Overview

• Mathematical modelling suggests annual multi-cancer blood tests could reduce late-stage cancer diagnoses by 49% and deaths by 21% within five years.
• Biennial screening is also effective, intercepting up to 39% of late-stage cases and reducing mortality by 17%.
• The NHS is trialling the Galleri and miONCO-Dx tests, including an 8,000-patient study on miONCO-Dx, which uses AI to detect 12 common cancers via microRNA analysis.
• Researchers aim to confirm the clinical benefits of these tests through large-scale randomized controlled trials, with definitive results expected by 2032.
• Experts emphasize the need for rigorous trials and cost negotiations to ensure feasibility and minimize risks like false positives before any national rollout.